Day: August 11, 2022

Viactiv® Product Line Contributes to Highest Quarterly Revenue in Company History of Approximately $3.275 Million, Shows Significant Revenue Growth from Prior Quarter HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) — Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the quarter ended June 30, 2022. The Company also provided a corporate update to stockholders. The financial highlights presented below were materially impacted by the Company’s June 1, 2021 acquisition of the Viactiv® line of supplement chews for bone health and other applications, which are profitably marketed...

Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe and Enrolling Patients Toward Interim Analysis Anticipated in Q1 2023 Camsirubicin Phase 1b Dose­-Escalation Trial Now Dosing 4th Level WILMETTE, Ill., Aug. 11, 2022 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced second quarter 2022 financial results and summarized recent program developments. Recent Program Developments Validive – International Phase 2b/3 VOICE Clinical Trial, Actively RecruitingThe VOICE trial continues to enroll patients and add additional clinical sites in the U.S. and Europe (now at 58 active sites). Based on...

KAPALUA RESORT, Hawaii, Aug. 11, 2022 (GLOBE NEWSWIRE) — Maui Land & Pineapple Company, Inc. (NYSE: MLP) reported net income of $10.5 million, or $0.54 per share, for the second quarter of 2022, compared to net income of $1.9 million, or $0.10 per share, for the second quarter of 2021. Total operating revenues of approximately $14.0 million and $5.0 million were recognized during the three months ended June 30, 2022 and 2021, respectively. For the six months ended June 30, 2022, the Company reported net income of $9.9 million, or $0.51 per share, compared to net income of $0.9 million, or $0.05 per share, for the six months ended June 30, 2021. Total operating revenues of approximately $16.2 million and $7.0 million were recognized during the six months ended June 30, 2022 and 2021, respectively. On May 20, 2022, the Company...

Exceeded annual Active Program guidance with ten programs signed year-to-date Executed strategic reorganization to extend cash runway into late-2025 VANCOUVER, Wash. and NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today reported financial and operating results for the quarter ended June 30, 2022. “As we pass the halfway point of 2022, our team continues to make excellent progress toward our stated objectives,” said Sean McClain, founder and CEO. “Since becoming a public company one year ago, we have signed 13 discovery programs and continue to see momentum with adoption of our technology, reflected in the discovery deals we’ve signed each...

Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half of 2022 License Agreement with Takeda to Develop and Commercialize a Novel Next-Generation Immuno-Oncology Bispecific Antibody Therapeutic FS118 Cleared the Futility Hurdle for the Initial Stage of the Head and Neck Acquired Resistance Cancer Trial Initiation of Combination Dosing with FS120 and KEYTRUDA® in Patients with Advanced Cancers under Supply Agreement with MSD Company Will Not be Hosting Q2 2022 Earnings Conference Call Due to the Pending Transaction with invoX PharmaCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) — F-star Therapeutics, Inc. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company pioneering bispecifics...

LAKEWOOD, NJ, Aug. 11, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Reliance Global Group, Inc. (Nasdaq: RELI; RELIW) (“Reliance”, “we” or the “Company”), which combines artificial intelligence (AI) and cloud-based technologies with the personalized experience of a traditional insurance agency, announced today that it will host a conference call on Monday, August 15, 2022, at 2:00 PM Eastern Time to discuss financial results for the quarter ended June 30, 2022, and provide a business update. The conference call will be available via telephone by dialing toll-free +1 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and entering access code 581329. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2381/46386 or on the investor relations section of the company’s website, https://ediblegarden.com/pages/webcasts-presentations. A...

   – Reported positive topline results from ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia patients; initiation of Phase 3 trial expected in the first half of 2023 – – ENTRIGUE data to be presented as a late-breaker at European Society of Cardiology Congress 2022 – – ENLIVEN Phase 2b NASH trial enrollment completion expected in the third quarter of 2022 followed by topline data in the first quarter of 2023 – – Completed underwritten offering, raising approximately $94.5 million in gross proceeds – SAN FRANCISCO, Aug. 11, 2022 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported...

-Prioritizing the advancement of novel oncolytic adenovirus (OV) platform- -Cash balance as of August 1, 2022 of $53.5 million, including the additional $3 million in gross proceeds from convertible preferred financing extends funding for business operations into Q1 2024- -Conference call and webcast to be held today at 8:30 a.m. ET- ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update. “We are pleased with the steady progress that continues to support the advancement of our novel OV platform and further underscores the potential value of our lead candidate, VCN-01,...

Revenue increase of 49% year-over-year CHICAGO, Aug. 11, 2022 (GLOBE NEWSWIRE) — Fast Radius, Inc. (“Fast Radius”) (Nasdaq: FSRD), a cloud manufacturing and digital supply chain company, reported financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Financial SummaryRevenue increased 49% to $7.3 million in second quarter 2022 compared to $4.9 million in second quarter 2021; Net loss was $22.2 million in second quarter 2022, or $0.29 per diluted share, compared to a net loss of $15.1 million, or $0.36 per diluted share, in second quarter 2021; Adjusted EBITDA loss was $17.3 million in second quarter 2022 compared to a loss of $13.5 million in second quarter 2021; and Total Bookings were $7 million in second quarter 2022, an increase of 13% compared to second quarter 2021.Management Commentary “In...

Phase 1 clinical trials of SZN-1326 and SZN-043 initiated and ongoing Preclinical proof-of-concept data for multiple programs presented and published in Q2 continue to validate Wnt modulation for tissue repairSOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today reported financial results for the second quarter of 2022 and provided a corporate update. “With the initiation of clinical trials for our lead therapeutic candidates, SZN-1326 and SZN-043, Surrozen became a clinical stage company in the second quarter of 2022,” said Craig Parker, President and Chief Executive Officer of Surrozen. “During the quarter we also presented data...